Literature DB >> 27619989

Mutational analysis of TP53 gene in Tunisian familial hematological malignancies and sporadic acute leukemia cases.

Walid Sabri Hamadou1, Sawsen Besbes2, Violaine Bourdon3, Yosra Ben Youssef4, Mohamed Adnène Laatiri5, Testsuro Noguchi3, Abderrahim Khélif4, Hagay Sobol3, Zohra Soua2.   

Abstract

Mutations are responsible for familial cancer syndromes which account for approximately 5-10 % of all types of cancers. Familial cancers are often caused by genetic alterations occurring either in tumor suppressor or genomic stability genes such as TP53. In this study, we have analyzed the TP53 gene by direct sequencing approach, in a panel of 18 Tunisian familial hematological malignancies cases including several forms of leukemia, lymphoma and myeloid syndrome and 22 cases of sporadic acute leukemia. In one familial case diagnosed with acute lymphoblastic leukemia, we reported an intronic substitution 559+1 G>A which may disrupt the splice site and impact the normal protein function. Most of the deleterious mutations (Arg158His; Pro282Trp; Thr312Ser) as classified by IARC data base, were commonly reported in ALL cases studied here. The cosegregation of the two variants rs1042522 and rs1642785 was observed in most patients which may be in favor of the presence of linkage disequilibrium. The most defined TP53 mutations found here were identified in acute lymphoblastic leukemia context whereas only 3 % of mutations have been in previous studies. The cosegregation of the two recurrent variant rs1042522 and rs1642785 should be further confirmed.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Acute myeloid leukemia; Familial hematological malignancies; TP53 gene mutations

Mesh:

Substances:

Year:  2017        PMID: 27619989     DOI: 10.1007/s10689-016-9931-3

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  24 in total

Review 1.  Blinded by the Light: The Growing Complexity of p53.

Authors:  Karen H Vousden; Carol Prives
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

2.  Lack of toxicity in a patient with germline TP53 mutation treated with radiotherapy.

Authors:  P Wong; K Han
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

3.  A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.

Authors:  Sona Pekova; Oldrich Mazal; Radek Cmejla; David W Hardekopf; Radek Plachy; Lenka Zejskova; Renata Haugvicova; Tereza Jancuskova; Michal Karas; Vladimir Koza; Lukas Smolej; Ludmila Bezdickova; Tomas Kozak
Journal:  Leuk Res       Date:  2011-01-13       Impact factor: 3.156

4.  Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.

Authors:  Sara Calhoun; Valerie Daggett
Journal:  Biochemistry       Date:  2011-05-17       Impact factor: 3.162

5.  Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.

Authors:  Jana Hof; Stefanie Krentz; Claudia van Schewick; Gabriele Körner; Shabnam Shalapour; Peter Rhein; Leonid Karawajew; Wolf-Dieter Ludwig; Karl Seeger; Günter Henze; Arend von Stackelberg; Christian Hagemeier; Cornelia Eckert; Renate Kirschner-Schwabe
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

Review 6.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

7.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.

Authors:  Kelly D Gonzalez; Katie A Noltner; Carolyn H Buzin; Dongqing Gu; Cindy Y Wen-Fong; Vu Q Nguyen; Jennifer H Han; Katrina Lowstuter; Jeffrey Longmate; Steve S Sommer; Jeffrey N Weitzel
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

Review 8.  Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer.

Authors:  Issa J Dahabreh; Christopher H Schmid; Joseph Lau; Vasileia Varvarigou; Samuel Murray; Thomas A Trikalinos
Journal:  Am J Epidemiol       Date:  2013-05-31       Impact factor: 4.897

Review 9.  p53 polymorphisms: cancer implications.

Authors:  Catherine Whibley; Paul D P Pharoah; Monica Hollstein
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

10.  Assessment of TP53 mutations in benign and malignant salivary gland neoplasms.

Authors:  Carolina Cavaliéri Gomes; Marina Gonçalves Diniz; Lissur Azevedo Orsine; Alessandra Pires Duarte; Thiago Fonseca-Silva; Brendan I Conn; Luiz De Marco; Cláudia Maria Pereira; Ricardo Santiago Gomez
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

View more
  2 in total

1.  Association of TP53 gene polymorphisms with the risk of acute lymphoblastic leukemia in Moroccan children.

Authors:  Hanaa Skhoun; Mohammed Khattab; Aziza Belkhayat; Zahra Takki Chebihi; Youssef Bakri; Nadia Dakka; Jamila El Baghdadi
Journal:  Mol Biol Rep       Date:  2022-06-15       Impact factor: 2.742

Review 2.  A Review of Cancer Genetics and Genomics Studies in Africa.

Authors:  Solomon O Rotimi; Oluwakemi A Rotimi; Bodour Salhia
Journal:  Front Oncol       Date:  2021-02-15       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.